GSK says application for Shingrix accepted for review in China

GSK plc announced that the Center for Drug Evaluation of the China National Medical Products Administration, or NMPA, has accepted for review the regulatory application of Shingrix for the prevention of shingles in adults aged 18 years and over at increased risk. The NMPA application is informed by six clinical trials in patients aged 18 years and over who had undergone recent blood-forming cells transplantation, kidney transplant, or have blood cancer, solid tumour, or HIV, the company stated.